Literature DB >> 24362690

Respiratory syncytial virus mechanisms to interfere with type 1 interferons.

Sailen Barik1.   

Abstract

Respiratory syncytial virus (RSV) is a member of the Paramyxoviridae family that consists of viruses with nonsegmented negative-strand RNA genome. Infection by these viruses triggers the innate antiviral response of the host, mainly type I interferon (IFN). Essentially all other viruses of this family produce IFN suppressor functions by co-transcriptional RNA editing. In contrast, RSV has evolved two unique nonstructural proteins, NS1 and NS2, to effectively serve this purpose. Together, NS1 and NS2 degrade or sequester multiple signaling proteins that affect both IFN induction and IFN effector functions. While the mechanism of action of NS1 and NS2 is a subject of active research, their effect on adaptive immunity is also being recognized. In this review, we discuss various aspects of NS1 and NS2 function with implications for vaccine design.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362690     DOI: 10.1007/978-3-642-38919-1_9

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  37 in total

1.  Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.

Authors:  Philippa Hillyer; Viraj P Mane; Aaron Chen; Maria B Dos Santos; Lynnsie M Schramm; Rachel E Shepard; Cindy Luongo; Cyril Le Nouën; Lei Huang; Lihan Yan; Ursula J Buchholz; Ronald G Jubin; Peter L Collins; Ronald L Rabin
Journal:  Virology       Date:  2017-01-31       Impact factor: 3.616

2.  2'-5'-Oligoadenylate Synthetase-Like Protein Inhibits Respiratory Syncytial Virus Replication and Is Targeted by the Viral Nonstructural Protein 1.

Authors:  Jayeeta Dhar; Rolando A Cuevas; Ramansu Goswami; Jianzhong Zhu; Saumendra N Sarkar; Sailen Barik
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 3.  Animal models of respiratory syncytial virus infection and disease.

Authors:  Randy E Sacco; Russell K Durbin; Joan E Durbin
Journal:  Curr Opin Virol       Date:  2015-07-11       Impact factor: 7.090

4.  Could boosting the oligoadenylate synthetase-like pathway bring a new era of antiviral therapy?

Authors:  Saumendra N Sarkar
Journal:  Future Virol       Date:  2014       Impact factor: 1.831

5.  Differential interferon gene expression in bronchiolitis caused by respiratory syncytial virus-A genotype ON1.

Authors:  Alessandra Pierangeli; Agnese Viscido; Camilla Bitossi; Federica Frasca; Massimo Gentile; Giuseppe Oliveto; Antonella Frassanito; Raffaella Nenna; Fabio Midulla; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2019-09-04       Impact factor: 3.402

Review 6.  Structure-Based Vaccine Antigen Design.

Authors:  Barney S Graham; Morgan S A Gilman; Jason S McLellan
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

Review 7.  Vaccine development for respiratory syncytial virus.

Authors:  Barney S Graham
Journal:  Curr Opin Virol       Date:  2017-05-16       Impact factor: 7.090

Review 8.  Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.

Authors:  Sara A Taleb; Asmaa A Al Thani; Khalid Al Ansari; Hadi M Yassine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-06       Impact factor: 3.267

9.  Differential Responses by Human Respiratory Epithelial Cell Lines to Respiratory Syncytial Virus Reflect Distinct Patterns of Infection Control.

Authors:  Philippa Hillyer; Rachel Shepard; Megan Uehling; Mina Krenz; Faruk Sheikh; Kalyn R Thayer; Lei Huang; Lihan Yan; Debasis Panda; Cindy Luongo; Ursula J Buchholz; Peter L Collins; Raymond P Donnelly; Ronald L Rabin
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

10.  Rational design of human metapneumovirus live attenuated vaccine candidates by inhibiting viral mRNA cap methyltransferase.

Authors:  Yu Zhang; Yongwei Wei; Xiaodong Zhang; Hui Cai; Stefan Niewiesk; Jianrong Li
Journal:  J Virol       Date:  2014-07-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.